UBS Initiates Coverage on Par Pharmaceutical (PRX) with a Buy; Small and Nimble is Interesting To Us
Tweet Send to a Friend
UBS initiates coverage on Par Pharmaceutical (NYSE: PRX) with a Buy rating. PT $35.
UBS analyst says, "We believe that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "We believe that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
